AR and posterior cortical atrophy: In addition, a novel drug called galaterone, which both inhibits androgen synthesis and promotes degradation of AR-FL and ARV7 [50, 95–97], is in Phase III trials for treatment of ARV7-positive CR-PCa patients (NCT02438007, https://clinicaltrials.gov/).